Clinical and Genomic Characterization of Chemoradiation-resistant HPV-positive Oropharyngeal Squamous Cell Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Mar 20

PMID 38505587

Authors

Theresa Guo

Fernando Zamuner

Stephanie Ting

Liam Chen

Lisa Rooper

Pablo Tamayo

Carole Fakhry

Daria Gaykalova

Ranee Mehra

Affiliations

Soon will be listed here.

Abstract

Introduction: Most patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) have an excellent response to chemoradiation, and trials are now investigating de-escalated treatment. However, up to 25% of patients with HPV-positive OPSCC will experience recurrence, and up to 5% will even progress through primary treatment. Currently, there are no molecular markers to identify patients with poor prognosis who would be harmed by de-escalation. Herein we report the clinical and genomic characteristics of persistent HPV-positive OPSCC after definitive platinum-based chemoradiation therapy.

Methods: Patients with HPV-positive OPSCC treated with curative intent platinum-based chemoradiation between 2007 and 2017 at two institutions and with a persistent locoregional disease were included. We evaluated clinical characteristics, including smoking status, age, stage, treatment, and overall survival. A subset of five patients had tissue available for targeted exome DNA sequencing and RNA sequencing. Genomic analysis was compared to a previously published cohort of 47 treatment-responsive HPV+ OPSCC tumors after batch correction. Mutational landscape, pathway activation, and OncoGPS tumor states were employed to characterize these tumors.

Results: Ten patients met the inclusion criteria. The tumor and nodal stages ranged from T1 to T4 and N1 to N2 by AJCC 8th edition staging. All patients were p16-positive by immunohistochemistry, and eight with available hybridization were confirmed to be HPV-positive. The 1-year overall survival from the time of diagnosis was 57%, and the 2-year overall survival was 17%. mutations were present in three of five (60%) persistent tumors compared to 2% (one of 47) of treatment-responsive HPV-positive tumors ( = 0.008). Other genes with recurrent mutations in persistent HPV-positive OPSCC tumors were , , , and . Compared to treatment-responsive HPV-positive tumors, persistent tumors demonstrated activation of DNA Repair and p53, EMT, MYC, SRC, and TGF-beta signaling pathways, with post-treatment samples demonstrating significant activation of the PI3K-EMT-Stem pathways compared to pretreatment samples.

Conclusion: Chemoradiation-resistant HPV-positive OPSCC occurs infrequently but portends a poor prognosis. These tumors demonstrate higher rates of p53 mutation and activation of MYC, SRC, and TGF-beta pathways. A comparison of tumors before and after treatment demonstrates PI3K-EMT-Stem pathways post-treatment in HPV-positive tumors with persistent disease after platinum-based chemoradiation.

References

An H, Jo H, Jung C, Kang J, Kim M, Sun D . Prognostic implication of ERCC1 protein expression in resected oropharynx and oral cavity cancer. Pathol Res Pract. 2017; 213(8):949-955. DOI: 10.1016/j.prp.2017.05.006. View

Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough W, Issaeva N . TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma. Cancer. 2017; 123(10):1778-1790. PMC: 5419871. DOI: 10.1002/cncr.30570. View

Maruyama H, Yasui T, Ishikawa-Fujiwara T, Morii E, Yamamoto Y, Yoshii T . Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci. 2014; 105(4):409-17. PMC: 4317800. DOI: 10.1111/cas.12369. View

Geiger J, Bauman J, Gibson M, Gooding W, Varadarajan P, Kotsakis A . Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head Neck. 2016; 38(12):1759-1764. PMC: 6820341. DOI: 10.1002/hed.24501. View

Guo T, Sakai A, Afsari B, Considine M, Danilova L, Favorov A . A Novel Functional Splice Variant of Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers. Cancer Res. 2017; 77(19):5248-5258. PMC: 6042297. DOI: 10.1158/0008-5472.CAN-16-3106. View

Citron F, Armenia J, Franchin G, Polesel J, Talamini R, DAndrea S . An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma. Clin Cancer Res. 2017; 23(14):3769-3780. PMC: 7309652. DOI: 10.1158/1078-0432.CCR-16-2814. View

Brisson R, Kochanny S, Arshad S, Dekker A, DeSouza J, Saloura V . A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. Head Neck. 2019; 41(11):3842-3849. PMC: 8258680. DOI: 10.1002/hed.25910. View

Harbison R, Kubik M, Konnick E, Zhang Q, Lee S, Park H . The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer. JCI Insight. 2018; 3(14). PMC: 6124437. DOI: 10.1172/jci.insight.99327. View

Haft S, Ren S, Xu G, Mark A, Fisch K, Guo T . Mutation of chromatin regulators and focal hotspot alterations characterize human papillomavirus-positive oropharyngeal squamous cell carcinoma. Cancer. 2019; 125(14):2423-2434. PMC: 6602825. DOI: 10.1002/cncr.32068. View

10.

Ang K, Harris J, Wheeler R, Weber R, Rosenthal D, Nguyen-Tan P . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1):24-35. PMC: 2943767. DOI: 10.1056/NEJMoa0912217. View

11.

Baugh E, Ke H, Levine A, Bonneau R, Chan C . Why are there hotspot mutations in the TP53 gene in human cancers?. Cell Death Differ. 2017; 25(1):154-160. PMC: 5729536. DOI: 10.1038/cdd.2017.180. View

12.

Kim S, Koo B, Kang S, Park K, Kim H, Lee K . HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer. 2007; 120(7):1418-25. DOI: 10.1002/ijc.22464. View

13.

Hanna G, Kacew A, Chau N, Shivdasani P, Lorch J, Uppaluri R . Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. JCI Insight. 2018; 3(17). PMC: 6171803. DOI: 10.1172/jci.insight.122799. View

14.

Patro R, Duggal G, Love M, Irizarry R, Kingsford C . Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017; 14(4):417-419. PMC: 5600148. DOI: 10.1038/nmeth.4197. View

15.

Ferris R, Flamand Y, Weinstein G, Li S, Quon H, Mehra R . Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2021; 40(2):138-149. PMC: 8718241. DOI: 10.1200/JCO.21.01752. View

16.

Masterson L, Moualed D, Liu Z, Howard J, Dwivedi R, Tysome J . De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer. 2014; 50(15):2636-48. DOI: 10.1016/j.ejca.2014.07.001. View

17.

Nulton T, Kim N, DiNardo L, Morgan I, Windle B . Patients with integrated HPV16 in head and neck cancer show poor survival. Oral Oncol. 2018; 80:52-55. PMC: 5930384. DOI: 10.1016/j.oraloncology.2018.03.015. View

18.

Day T, Shirai K, OBrien P, Matheus M, Godwin K, Sood A . Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. Clin Cancer Res. 2018; 25(4):1156-1164. PMC: 6377824. DOI: 10.1158/1078-0432.CCR-18-2024. View

19.

. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536):576-82. PMC: 4311405. DOI: 10.1038/nature14129. View

20.

Pinatti L, Sinha H, Brummel C, Goudsmit C, Geddes T, Wilson G . Association of human papillomavirus integration with better patient outcomes in oropharyngeal squamous cell carcinoma. Head Neck. 2020; 43(2):544-557. PMC: 7898416. DOI: 10.1002/hed.26501. View